Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Down – Time to Sell?

Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $14.42, but opened at $13.62. Astellas Pharma shares last traded at $13.9350, with a volume of 11,430 shares changing hands.

Analysts Set New Price Targets

Separately, Zacks Research lowered Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Astellas Pharma presently has an average rating of “Hold”.

Get Astellas Pharma alerts:

Check Out Our Latest Analysis on Astellas Pharma

Astellas Pharma Stock Performance

The stock has a market cap of $24.78 billion, a P/E ratio of 12.75 and a beta of 0.07. The stock has a fifty day simple moving average of $13.43 and a 200-day simple moving average of $14.64. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.90 and a current ratio of 1.17.

Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) last released its earnings results on Monday, April 27th. The company reported $0.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.14. Astellas Pharma had a return on equity of 23.54% and a net margin of 13.66%.The business had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.28 billion. On average, equities analysts expect that Astellas Pharma Inc. will post 1.25 earnings per share for the current year.

About Astellas Pharma

(Get Free Report)

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).

Further Reading

• Five stocks we like better than Astellas Pharma
• Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
• Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
• Apple’s Record Quarter Could Not Outrun Its Guidance Problem
• McKesson’s Compounding Keeps Adding Up

Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.